The Moffitt Cancer Center requests renewal of its NCI Cancer Center Support Grant (CCSG) for years 14-18. Moffitt is a free-standing cancer center whose sole mission is """"""""to contribute to the prevention and cure of cancer."""""""" Research activities are focused around five programs: Molecular Oncology &Drug Discovery;Immunology;Experimental Therapeutics;Cancer Epidemiology, and Health Outcomes &Behavior. Fourteen shared resources provide broad support for these programs and our faculty. Over the last grant period, Moffitt has made significant progress. Extramural funding increased from $54.0 million to 82.6 million. Membership increased from 135 to 156 including the recruitment of 67 new faculty. Over 1,900 peer-reviewed publications were generated over the last 5 years by Moffitt members. Clinical intervention trial accrual averaged 1,176 subjects per year. Facilities projects included an $87 million investment that added 36 hospital beds, 40,000 sf of faculty office space, 2 linear accelerators and related support space that included an expanded Clinical Research Unit. A nexus freezer system, a fully automated and robotic biorepository system with a capacity of over 2.4 million tubes, was installed. Moffitt has invested in strategic initiatives to enhance our basic, population and clinical researc to strengthen the research programs and spur collaboration. These major initiatives include Total Cancer Care, Moffitt's bold long-term initiative to realize personalized cancer care by incorporating information on molecular characterization of the host and tumor into treatment decisions. Other initiatives include investments in lung cancer, melanoma, imaging research, integrated mathematical oncology, health disparities and diversity, and education and training. The Moffitt proposal includes funding requests for 5 programs, 14 shared resources, and 7 staff investigators. The increased budget will provide critical resources to support and enhance the Center's infrastructure, particularly the shared resources. The institution, with generous support from the State, has developed a solid research infrastructure that has successfully supported a rapid increase in peer-reviewed funding and publications in a short amount of time. We believe our success to date represents a healthy return on investment made by the NCI and the state of Florida.

Public Health Relevance

The Cancer Center Support Grant will provide Moffitt with resources for critical infrastructure to reduce the cancer burden throughout Florida and across the United States. Moffitt's singular focus on cancer and obligation to serve as the State of Florida's cancer center positions the center to make significant contributions to the prevention and cure of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-14
Application #
8214821
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-02-18
Project End
2017-01-31
Budget Start
2012-06-22
Budget End
2013-01-31
Support Year
14
Fiscal Year
2012
Total Cost
$2,787,198
Indirect Cost
$1,218,252
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :
Karolak, Aleksandra; Estrella, Veronica C; Huynh, Amanda S et al. (2018) Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling. Sci Rep 8:3638
Barata, Anna; Gonzalez, Brian D; Sutton, Steven K et al. (2018) Coping strategies modify risk of depression associated with hematopoietic cell transplant symptomatology. J Health Psychol 23:1028-1037
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Kazi, Aslamuzzaman; Xiang, Shengyan; Yang, Hua et al. (2018) GSK3 suppression upregulates ?-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun 9:5154
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Kang, Sokbom; Thompson, Zachary; McClung, E Claire et al. (2018) Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer 28:260-266

Showing the most recent 10 out of 1254 publications